Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (F:GU5) — Market Cap & Net Worth
Market Cap & Net Worth: Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (GU5)
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (F:GU5) has a market capitalization of $367.63 Million (€314.46 Million) as of September 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #13963 globally and #1417 in its home market, demonstrating a -0.69% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's stock price €1.43 by its total outstanding shares 219900000 (219.90 Million). Also see Guangzhou Baiyunshan Pharmaceutical Hold asset portfolio for a full breakdown of the balance sheet.
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Market Cap History: 2015 to 2026
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's market capitalization history from 2015 to 2026. Data shows growth from $50.54 Million to $367.63 Million (20.08% CAGR). Also see GU5 cash flow metrics for how efficiently the company converts equity into cash flow.
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check current stock price of Guangzhou Baiyunshan Pharmaceutical Hold for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.01x
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's market cap is 0.01 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.17x
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's market cap is 0.17 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $57.10 Million | $20.04 Billion | $1.51 Billion | 0.00x | 0.04x |
| 2017 | $66.59 Million | $20.95 Billion | $2.06 Billion | 0.00x | 0.03x |
| 2018 | $96.79 Million | $42.23 Billion | $3.44 Billion | 0.00x | 0.03x |
| 2019 | $102.29 Million | $64.95 Billion | $3.19 Billion | 0.00x | 0.03x |
| 2020 | $91.99 Million | $61.67 Billion | $2.92 Billion | 0.00x | 0.03x |
| 2021 | $157.88 Million | $69.01 Billion | $3.72 Billion | 0.00x | 0.04x |
| 2022 | $262.49 Million | $70.79 Billion | $3.97 Billion | 0.00x | 0.07x |
| 2023 | $334.26 Million | $75.52 Billion | $4.06 Billion | 0.00x | 0.08x |
| 2024 | $550.16 Million | $74.99 Billion | $2.84 Billion | 0.01x | 0.19x |
| 2025 | $501.32 Million | $77.66 Billion | $2.98 Billion | 0.01x | 0.17x |
Competitor Companies of GU5 by Market Capitalization
Companies near Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited in the global market cap rankings as of September 19, 2026. Review Guangzhou Baiyunshan Pharmaceutical Hold (GU5) tangible net worth to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited by market ranking:
- McKesson Corporation (NYSE:MCK): Ranked #249 globally with a market cap of $101.38 Billion USD.
- Cencora Inc. (NYSE:COR): Ranked #544 globally with a market cap of $50.53 Billion USD.
- Cardinal Health Inc (NYSE:CAH): Ranked #645 globally with a market cap of $43.01 Billion USD.
- Sigma Healthcare Ltd (AU:SIG): Ranked #1240 globally with a market cap of $20.83 Billion USD ( AU$29.44 Billion AUD).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #249 | McKesson Corporation | NYSE:MCK | $101.38 Billion | $874.65 |
| #544 | Cencora Inc. | NYSE:COR | $50.53 Billion | $308.78 |
| #645 | Cardinal Health Inc | NYSE:CAH | $43.01 Billion | $225.38 |
| #1240 | Sigma Healthcare Ltd | AU:SIG | $20.83 Billion | AU$2.55 |
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Historical Marketcap From 2015 to 2026
Between 2015 and today, Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's market cap moved from $50.54 Million to $ 367.63 Million, with a yearly change of 20.08%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €367.63 Million | -26.67% |
| 2025 | €501.32 Million | -8.88% |
| 2024 | €550.16 Million | +64.59% |
| 2023 | €334.26 Million | +27.35% |
| 2022 | €262.49 Million | +66.26% |
| 2021 | €157.88 Million | +71.63% |
| 2020 | €91.99 Million | -10.08% |
| 2019 | €102.29 Million | +5.68% |
| 2018 | €96.79 Million | +45.37% |
| 2017 | €66.59 Million | +16.61% |
| 2016 | €57.10 Million | +12.97% |
| 2015 | €50.54 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $367.63 Million USD |
| MoneyControl | $367.63 Million USD |
| MarketWatch | $367.63 Million USD |
| marketcap.company | $367.63 Million USD |
| Reuters | $367.63 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited engages in the pharmaceutical and healthcare industry in the People's Republic of China and internationally. The company operates through Modern Chinese Medicine Business, Chemical Pharmaceutical Technology Business, Natural Beverage Business, Pharmaceutical Commercial Business, and Other segments. It is involved in the research, develo… Read more